$200K — $250K *
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVXCoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 data of the Phase 1/2 clinical trial. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
Overview of responsibilities:
The Senior Director, Health Economics and Outcomes Research (HEOR) role sits within the evidence generation function of the Medical Affairs organization and interacts with Payer and Commercial teams to design and implement observational research strategies in support of Novavax products. This role will be responsible for focusing on the generation of evidence to assist payers and health care provider (HCP) decision-makers understand the value our products bring to the market. This position will lead the internal and external communication of economic value proposition and of scientific results to achieve maximal scientific impact and commercial success of Novavax products. This position requires an experienced individual with expert scientific knowledge of HEOR and its application throughout development process, strong business acumen, and excellent interpersonal skills.
The Senior Director will lead the development and execution of the evidence generation strategy to demonstrate product clinical and economic value. This role will provide input to brand strategy the medical plan, payer-related evidence plans, and market access & pricing strategy. This position will lead the response to value reviews of Novavax products by external organizations, as appropriate and in alignment with Medical Affairs and commercial strategy. The director will ensure evidence strategy alignment with Medical Affairs, reimbursement, and regulatory strategies. This role will serve as the observational research expert for all Novavax products and will assist in the development and execution of post-authorization studies including post-authorization safety studies. The director will remain actively aware of the product environment by establishing, maintaining, and fostering internal (cross-functional, within the US and Global organizations) and external interactions with scientific experts.
Valid through: 11/2/2020
$200K — $250K
19 days ago